NCT05302648View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Human Derived anti-BCMA CAR-T Injection

Autologous genetically modified anti-BCMA CAR transduced T cells

Trial Locations (1)

200005

Shanghai Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY